Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

  1. Kong, A.
  2. Rea, D.
  3. Ahmed, S.
  4. Beck, J.T.
  5. López, R.L.
  6. Biganzoli, L.
  7. Armstrong, A.C.
  8. Aglietta, M.
  9. Alba, E.
  10. Campone, M.
  11. Schmitz, S.-F.H.
  12. Lefebvre, C.
  13. Akimov, M.
  14. Lee, S.-C.
Zeitschrift:
Oncotarget

ISSN: 1949-2553

Datum der Publikation: 2016

Ausgabe: 7

Nummer: 25

Seiten: 37680-37692

Art: Artikel

DOI: 10.18632/ONCOTARGET.8974 GOOGLE SCHOLAR lock_openOpen Access editor